Catalyst Pharmaceuticals, Inc. (CPRX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
As of 11:50AM EDT. Market open.
| Previous Close | 15.06 |
| Open | 15.00 |
| Bid | 15.04 x 100 |
| Ask | 15.16 x 100 |
| Day's Range | 14.77 - 15.20 |
| 52 Week Range | 11.55 - 17.50 |
| Volume | |
| Avg. Volume | 1,120,577 |
| Market Cap | 1.784B |
| Beta (5Y Monthly) | 0.73 |
| PE Ratio (TTM) | 26.96 |
| EPS (TTM) | 0.56 |
| Earnings Date | Jun 17, 2024 - Jun 23, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.29 |
ZacksWhy Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Simply Wall St.Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Been Rising: Are Strong Financials Guiding The Market?
Most readers would already know that Catalyst Pharmaceuticals' (NASDAQ:CPRX) stock increased by 4.1% over the past...
GlobeNewswireCatalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE® (amifampr
© 2024 Yahoo. All rights reserved.